Abstracts Archive - Page 173 of 2607 - ACR Meeting Abstracts

Abstract Number: 1121 • ACR Convergence 2025
Latent Class Analysis Identifies Distinct Phenotypes of Multisystem Immune-Related Adverse Events Predictive of Survival After Immune Checkpoint Inhibitors
Tao Ming Sim¹, May Shuen Tang¹, Qai Ven Yap², Alvin Wong¹, Yiqing Huang¹ and Frank Sen Hee Tay¹, ¹National University Hospital, Singapore, Singapore, ²National University of Singapore, Singapore
Background/Purpose: Use of immune checkpoint inhibitors (ICIs) can lead to a broad spectrum of immune-related adverse events (irAEs) affecting multiple organ systems. No clear pattern…
Abstract Number: 1045 • ACR Convergence 2025
Bayesian Analysis of Factors Associated with Romosozumab Adherence Among Early Adopters in Medicare Beneficiaries
Hongke Wu¹, Ye Liu¹, Tarun Arora² and Jeffrey Curtis³, ¹University of Alabama at Birmingham, Birmingham, AL, ²FASTER, Birmingham, AL, ³Foundation for Advancing Science, Technology, Education and Research, Birmingham, AL
Background/Purpose: : Early adherence data for newly approved drugs guide clinical management, yet small cohorts hamper conventional analyses. Romosozumab (Romo), licensed April 2019 for high-risk…
Abstract Number: 1087 • ACR Convergence 2025
Impact of Neighborhood-Level Social Vulnerability on Disease Severity, Clinical Manifestations, and Early Mortality in Systemic Lupus Erythematosus
Zoe Reed¹, Catriona Wagner², Xana Howard¹, Alexandre Cammarata-Mouchtouris¹, Study Team ALE⁰⁶ Clinical¹, Wade DeJager³ and Judith James¹, ¹Oklahoma Medical Research Foundation, Oklahoma City, OK, ²Oklahoma Medical Research Foundation, Santa Cruz, CA, ³Oklahoma Medical Research Foundation, Oklahoma City
Background/Purpose: Systemic lupus erythematosus (SLE) is a chronic autoimmune disease with considerable clinical and molecular heterogeneity. Significant disparities exist in SLE, with minority populations experiencing…
Abstract Number: 1145 • ACR Convergence 2025
Numerically Reduced but MSU Crystal-Activated NK Cells Promote Osteoclastogenesis in Gout
Ki-Jeong Park¹, Young-Nan Cho², Hye-Mi Jin², Hye-Min Jeong², Sung-Eun Choi³, Ji-Hyoun Kang¹, Dong-Jin Park¹, Tae-jong Kim⁴, Shin-Seok Lee⁵ and Yong-Wook Park⁶, ¹Chonnam National University Hospital, Gwangju, Republic of Korea, ²Chonnam National University Medical School, Gwangju, Republic of Korea, ³Chonnam National University Medical School & Hospital, Gwangju, Republic of Korea, ⁴Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwang-Ju, South Korea, ⁵Chonnam National University Medical School and Hospital, Gwangju, Republic of Korea, ⁶Department of Rheumatology, Chonnam National University Medical School and Hospital, Gwangju, South Korea
Background/Purpose: Gout is an inflammatory arthritis characterized by acute attacks, tophi formation, and bone destruction triggered by inflammatory responses to monosodium urate (MSU) crystals. Natural…
Abstract Number: 1134 • ACR Convergence 2025
Efficacy and Safety of Anakinra for Acute Calcium Pyrophosphate Deposition Disease Flare: A Systematic Review and Meta-Analysis
Pannathorn Nakaphan¹, Somkiat Phutinart², Patavee Pajareya², Priabprat Jansem³, Nattanicha Chaisrimaneepan⁴, Pim Jetanalin⁵ and Noppachai Siranart², ¹Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, ²Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, ³Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, ⁴Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX, ⁵Department of Medicine, Division of Rheumatology, University of Illinois College of Medicine, Chicago, IL
Background/Purpose: Calcium Pyrophosphate Deposition Disease (CPPD) is a common inflammatory arthritis among older adults. Comorbidities often limit conventional treatment of acute CPPD flare. Anakinra, an…
Abstract Number: 1115 • ACR Convergence 2025
Evaluation Of The Global Toxicity Burden In Patients Treated With Checkpoint Inhibitors Addressed For a Rheumatologic Toxicity And Its Impact On Oncological Outcomes
Juliette quelain¹, Eleonore Mourre², Julien Henry¹, Rakiba Belkir³, Andrew Cope⁴, Debashis Sarker⁵, Yin Wu⁶, Matthaios Kapiris⁷, Aurelien Marabelle⁸, Caroline Robert⁸, Raphaele Seror⁹, Xavier Mariette¹⁰ and Samuel Bitoun¹, ¹APHP, PARIS, France, ²APHP, PARIS, ³PARIS, PARIS, France, ⁴King's College London, London, United Kingdom, ⁵Comprehensive Cancer Centre and Consultant Medical Oncologist at Guy's, St Thomas' and King's College Hospitals., London, United Kingdom, ⁶Honorary Consultant Medical Oncologist at Guy's and St Thomas' NHS Foundation Trust, London, United Kingdom, ⁷KCL, LONDON, United Kingdom, ⁸IGR, PARIS, France, ⁹Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR¹¹⁸⁴: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, ¹⁰Université Paris-Saclay, Le Kremlin Bicetre, France
Background/Purpose: Approvals for immune checkpoint inhibitors (ICIs) have expanded, and triple therapy combining anti-PD-1, anti-CTLA-4, and anti-LAG3 have been evaluated with encouraging results. But they…
Abstract Number: 1053 • ACR Convergence 2025
Trends in Cost and Utilization of Biologic Medications for Rheumatologic Conditions: A Medicare Claims Study (2013–2022)
Taylor Koenig, Cleveland Clinic, Rocky River, OH
Background/Purpose: Biologic therapies have transformed rheumatologic disease management over the past two decades. As utilization of these high-cost medications increases and additional biologic and biosimilar…
Abstract Number: 1151 • ACR Convergence 2025
A Comparison of Patients with Cardiac Sarcoidosis vs. Other Systemic Manifestations of Sarcoidosis: A Retrospective Cohort Study
Chelsea Guan¹, Dana Nachawati¹, Amir Daneshvar¹, Keri Ann Pfeil¹, Elleson Harper¹, Lindsay Frumker², Meghan Gump¹, Vicky Nahra³ and Omer Pamuk⁴, ¹University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland, OH, ²University hospitals Cleveland medical center, Highland Heights, OH, ³University Hospitals Cleveland Medical Center/Case Western Reserve University, Cleveland Heights, OH, ⁴University Hospitals Cleveland Medical Center/ Case Western Reserve University, Cleveland, OH
Background/Purpose: Sarcoidosis is a systemic autoimmune disease with multiorgan involvement. In this study, we analyzed the differences in characteristics in patients with sarcoid myocarditis (cardiac…
Abstract Number: 1147 • ACR Convergence 2025
Renal Manifestations in VEXAS Syndrome: A Systematic Review of Clinical Features, Pathology, and Outcomes
Akhila Arya Perumangote Vasudevan¹, Vishnu Mulavini², Rasiya Hashim³, Madhumitha Rondla⁴ and Dileep C Unnikrishnan⁵, ¹Yale University/Bridgeport Hospital, Stratford, CT, ²Calicut Medical College, Stratford, ³Franciscan Health Olympia & Chicago Heights, [email protected], IL, ⁴Texas tech university health sciences center, El paso, El Paso, TX, ⁵Bridgeport Hospital, Stratford, CT
Background/Purpose: VEXAS syndrome is a recently described, adult-onset autoinflammatory disease caused by somatic mutations in the UBA1 gene, typically affecting hematopoietic stem cells. Renal involvement…
Abstract Number: 1097 • ACR Convergence 2025
Polymyalgia rheumatica and giant cell arteritis induced by immune checkpoint inhibitors: a systematic review and meta-analysis highlighting differences with the idiopathic forms
Elvis Hysa¹, Andrea Casabella², Emanuele Gotelli³, Rosanna Campitiello⁴, Carlo Genova⁴, Enrica Teresa Tanda⁴, Carmen Pizzorni⁵, Alberto Sulli⁵, Vanessa Smith⁶, Marco Amedeo Cimmino⁷, Sabrina Paolino⁵ and Maurizio Cutolo⁴, ¹University of Genoa, Genoa, Italy, ²IRCCS Ospedale Policlinico San Martino, Genova, Italy, ³University of Genoa, Genoa, Liguria, Italy, ⁴University of Genova, Genova, Italy, ⁵University of Genoa, Genova, Italy, ⁶Ghent University Hospital, Gent, Belgium, ⁷Rheumatology Outpatient Clinic, Villa Ravenna, Chiavari, Italy, Genova, Italy
Background/Purpose: An altered immune tolerance disturbed by immune checkpoint inhibitors (ICIs) may contribute to new-onset polymyalgia rheumatica (PMR) and giant cell arteritis (GCA) in treated…
Abstract Number: 1140 • ACR Convergence 2025
PGG Suppresses MSU Crystal–Triggered Inflammation and Arachidonic Acid Production in PBMCs
Sadiq Umar¹, Poorna Chandra Rao Yalagala², Sugasini Dhavamani² and Sriram Ravindran², ¹University of Illinois at Chicago, Chicago, IL, ²University of Illinois, Chicago, IL
Background/Purpose: Gout is the most prevalent inflammatory arthritis globally, with rising incidence in both developed and developing regions. It is driven by monosodium urate (MSU)…
Abstract Number: 1056 • ACR Convergence 2025
High diagnostic rate of genetic testing in adult patients with autoinflammation: A Single Center Experience
Atif Towheed¹, Joshua Owens², Ann Parody¹ and Daniella Schwartz³, ¹University of Pittsburgh Medical Centre, Pittsburgh, ²UPMC Children’s Hospital of Pittsburgh, Pittsburgh, ³University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Inborn errors of immunity (IEI), including autoinflammatory diseases and primary immune regulation disease (PIRD), are unfamiliar to many adult rheumatologists, leading to potential ascertainment…
Abstract Number: 1158 • ACR Convergence 2025
Clinical and Genetic Features of CTLA-4 Haploinsufficiency : A Prospective Study in China
Guishan Liu¹, Jingyuan zhang², jin Xu², JiaYuan Dai² and Min Shen², ¹Peking union medical college hospital, Beijing, Beijing, China (People's Republic), ²Peking union medical college hospital, Beijing, China (People's Republic)
Background/Purpose: Heterozygous loss-of-function mutations in CTLA4 cause a spectrum of immune dysregulation, characterized by hypogammaglobulinemia, autoimmune cytopenias, and lymphoproliferation, yet penetrance and expressivity remain highly…
Abstract Number: 1156 • ACR Convergence 2025
Incidence and Prevalence of Interstitial Pneumonia with Autoimmune Features in a Population-Based Cohort
elena Joerns¹, Sara Achenbach¹, Cynthia Crowson², eva carmona¹, Robert Vassallo³, John Joerns¹, Vanessa Kronzer³, John Davis³ and Elena myasoedova³, ¹Mayo Clinic, Rochester, ²Mayo Clinic, Stewartvillle, MN, ³Mayo Clinic, Rochester, MN
Background/Purpose: Interstitial pneumonia with autoimmune features (IPAF) is a type of interstitial lung disease (ILD) with features of autoimmunity, yet patients do not fulfill criteria…
Abstract Number: 1159 • ACR Convergence 2025
IL-18 Correlates with Pouchot Score and Inflammatory Biomarkers in Adult-Onset Still’s Disease: Insights From a Repeated Measures Study
Hadeel Abdul-Rehman¹, Karen Gambina² and Bella Mehta³, ¹Hospital for Special Surgery, New York, NY, ²Columbia University Medical Center, Islip, NY, ³Hospital for Special Surgery, Weill Cornell Medicine, Jersey City, NJ
Background/Purpose: Adult-Onset Still’s Disease (AOSD) is a rare systemic inflammatory disease. Interleukin-18 (IL-18) levels are significantly elevated in AOSD patients¹ and may be a promising…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].